

Application No. 10/580,588  
Paper Dated January 17, 2008  
Attorney Docket No. 3824-061668

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/580,588  
Applicants : Yutaka Sashida et al.  
Filed : May 25, 2006  
Title : Novel Compound and Pharmaceutical Composition  
Art Unit : 1614  
Examiner Name : Not Yet Assigned  
Confirmation No. : 5444  
Customer No. : 28289

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby submit this Information Disclosure Statement (IDS), together with completed Form PTO/SB/08a, Form PTO/SB/08b and a copy of each reference listed thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 17, 2008.

Bruce L. White

(Name of Person Mailing Paper or Fee)

*Bruce L. White*

Signature

01/17/2008

Date

The above-identified application is the U.S. national phase of PCT/JP2004/017480, filed November 25, 2004.

Some of the references listed on PTO/SB/08a were cited in an International Search Report (ISR), dated April 5, 2005 and/or an International Preliminary Report on Patentability (IPRP), dated August 3, 2006 in the corresponding PCT application. Copies of the ISR and IPRP are enclosed herewith.


Some of the references listed on PTO/SB/08a were cited in Office Actions in one of the priority Japanese patent applications. Copies of the Japanese Office Actions are enclosed herewith. English-language abstracts of the references cited by the Japanese Office Actions are also enclosed herewith.

Some of the references listed on Form PTO/SB/08a and Form PTO/SB/08b are cited in the specification of the application at page 1 and page 6, and are relevant for the reasons discussed therein.

Since this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits, it is timely under 37 C.F.R. §1.97(b)(3) and no fee is required. The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

By 

Richard L. Byrne  
Registration No. 28,498  
Attorney for Applicants  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, Pennsylvania 15219  
Telephone: 412-471-8815  
Facsimile: 412-471-4094  
E-mail: Webblaw@webblaw.com